Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease

Kidney International

Volumn 83, Issue 3, 2013, Pages 511-516

  Munyentwali, Helene ^a   Bouachi, Khedidja ^b,c   Audard, Vincent ^b,c,d   Remy, Philippe ^b,c   Lang, Philippe ^b,c,d   Mojaat, Rachid ^a   Deschênes, Georges ^e   Ronco, Pierre M ^a,f,g   Plaisier, Emmanuelle M ^a,f,g   Dahan, Karine Y ^a  

^a HÔPITAL TENON   (France)

^b UNIVERSITÉ PARIS EST   (France)

^c Reference Center for Idiopathic Nephrotic Syndrome   (France)

^d INSERM U955   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f INSERM   (France)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

clinical nephrology; glomerulopathy; nephrotic syndrome

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CD19 ANTIGEN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEFLOXACIN; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ACNE; ADULT; BONE NECROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GROWTH RETARDATION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; MUSCLE ATROPHY; OSTEOPOROSIS; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874663759     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.444     Document Type: Article

References (33)

1. Tarshish P, Tobin JN, Bernstein J et al. Prognostic significance of the early course of minimal change nephrotic syndrome: Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8: 769-776
2. Niaudet P. Steroid-sensitive idiopathic nephrotic syndrome in children. In: Avner E, Harmon W, Niaudet P (eds). Pediatric Nephrology, 5th edn Lippincott Williams & Wilkins: Philadelphia, 2004; pp 543-556
3. Kyrieleis HAC, Löwik MM, Pronk I et al. Long-term outcome of biopsy proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 2009; 4: 1593-1600
4. Fakhouri F, Bocquet N, Taupin P et al. Steroid-sensitive nephrotic syndrome: From childhood to adulthood. Am J Kidney Dis 2003; 41: 550-557
5. Hodson E, Willis N, Craig J. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev 2008; 23: CD002290
6. Bagga A, Hari P, Moudgil A et al. Mycophe'nolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 2003; 42: 1114-1120
7. Kyrieleis HA, Levtchenko EN, Wetzels JFM. Long-term outcome after cyclophosphamide treatment in children with steroid dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis 2007; 49: 592-597
8. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8(Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non Hodgkin's lymphoma. Blood 1997; 90: 2188-2195
9. Smith KG, Jones RB, Burns SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematous and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982
10. Dörner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010; 125: 464-475
11. Remuzzi G, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-924
12. Fervenza FC, Cozio FG, Erickson SB et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73: 117-125
13. Haffner D, Fischer DC. Nephrotic syndrome and rituximab: Facts and perspectives. Pediatr Nephrol 2009; 24: 1433-1438
14. Guigonis V, Dallocchio A, Baudouin V et al. Rituximab treatment for severe steroid-or cyclosporine dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr Nephrol 2008; 23: 1269-1279
15. Kamei K, Ito S, Nozu K et al. Single dose of rituximab for refractory steroiddependent nephrotic syndrome in children. Pediatr Nephrol 2009; 24: 1321-1328
16. Sellier-Leclerc AL, Macher MA, Loirat C et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25: 1109-1115
17. Gulati A, Sinha A, Jordan SC et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: Multicentric report. Clin J Am Soc Nephrol 2010; 5: 2207-2212
18. Fujinaga S, Hirano D, Nishizaki N et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010; 25: 539-544
19. Kemper MJ, Gellermann J, Habbig S et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1910-1915
20. Ravani P, Magnasco A, Edefonti A et al. Short-term effects of rituximab in children with steroid-and calcineurin-dependent nephrotic syndrome: A randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 1308-1315
21. Sinha A, Bagga A, Gulati A et al. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2012; 27: 235-241
22. François H, Daugas E, Bensman A et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: First case report and pathophysiological considerations. Am J Kidney Dis 2007; 49: 158-161
23. Beco A, Castro-Ferreira I, Coentrao L et al. Rituximab for steroiddependent nephrotic syndrome. Clin Nephrol 2010; 74: 308-310
24. Kurosu N, Sugiura H, Iwasaki C et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroidresistant nephrotic syndrome. Intern Med 2009; 48: 1901-1904
25. Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 2011; 76: 151-158
26. Dantal J, Bigot E, Bogers W et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7-14
27. Kemper MJ, Wolf G, Muller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 2001; 344: 386-387
28. Shaloub RJ. Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 1974; 2: 556-560
29. Takei T, Nitta K. Rituximab and minimal change nephrotic syndrome: A therapeutic option. Clin Exp Nephrol 2011; 15: 641-647
30. Bruneau S, Dantal J. New insights into the pathophysiology of idiopathic nephrotic syndrome. Clin Immunol 2009; 133: 13-21
31. Fornoni A, Sageshima J, Wei C et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46
32. Fernandez-Fresnedo G, Segarra A, Gonza'lez E et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009; 4: 1317-1323
33. Kari JA, El-Morshedy SM, El-Desoky S et al. Rituximab for refractory cases of childhood nephrotic syndrome. Pediatr Nephrol 2011; 26: 733-737